Therapy could increase ovarian cancer survival, paper finds – Drug Discovery World (DDW)

January 15, 2026 Therapy could increase ovarian cancer survival, paper finds - Drug Discovery World (DDW) This article was originally published in Drug Discovery World A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals. A new clinical study, published in the International Journal of Gynecological Cancer , shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival rates for patients with the deadliest form of ovarian cancer. Analysis shows women who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone, with median overall survival increasing from approximately 13 months to over 25 months. The risk of death was also reduced by nearly 60%. “As a gynaecologic oncologist, I see firsthand how devastating platinum-resistant ovarian cancer is for patients and their families,” said Dr Gabriel Levin, Gynaecologic Oncologist at McGill University Health Centre and co-author of the study. “What makes these findings so meaningful is not only the improvement in survival but the fact that this was achieved without adding toxicity. Our hope is that therapies like Elenagen can shift how we think about cancer treatment by supporting the body’s biology rather than simply escalating chemotherapy.”

The release as fetched from its publisher. curelaboncology.com ↗